JP2014534956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534956A5 JP2014534956A5 JP2014533950A JP2014533950A JP2014534956A5 JP 2014534956 A5 JP2014534956 A5 JP 2014534956A5 JP 2014533950 A JP2014533950 A JP 2014533950A JP 2014533950 A JP2014533950 A JP 2014533950A JP 2014534956 A5 JP2014534956 A5 JP 2014534956A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- use according
- patient
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 103
- 239000003112 inhibitor Substances 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 12
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- 102000015685 human GM-CSF receptor-alpha subunit Human genes 0.000 claims description 9
- 108010038879 human GM-CSF receptor-alpha subunit Proteins 0.000 claims description 9
- 229960000485 methotrexate Drugs 0.000 claims description 9
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 239000003435 antirheumatic agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 26
- 238000003556 assay Methods 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 102220627452 Paired immunoglobulin-like type 2 receptor alpha_L95A_mutation Human genes 0.000 description 1
- KLAONOISLHWJEE-QWRGUYRKSA-N Phe-Gln Chemical group NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KLAONOISLHWJEE-QWRGUYRKSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545359P | 2011-10-10 | 2011-10-10 | |
| US61/545,359 | 2011-10-10 | ||
| US201161556974P | 2011-11-08 | 2011-11-08 | |
| US61/556,974 | 2011-11-08 | ||
| PCT/EP2012/070074 WO2013053767A1 (en) | 2011-10-10 | 2012-10-10 | Treatment for rheumatoid arthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534956A JP2014534956A (ja) | 2014-12-25 |
| JP2014534956A5 true JP2014534956A5 (enExample) | 2015-11-26 |
| JP6239517B2 JP6239517B2 (ja) | 2017-11-29 |
Family
ID=47010599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533950A Active JP6239517B2 (ja) | 2011-10-10 | 2012-10-10 | 関節リウマチの治療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140335081A1 (enExample) |
| EP (1) | EP2766394B1 (enExample) |
| JP (1) | JP6239517B2 (enExample) |
| CN (1) | CN103906767A (enExample) |
| AU (2) | AU2012322991B2 (enExample) |
| CA (1) | CA2851322C (enExample) |
| ES (1) | ES2660776T3 (enExample) |
| RU (1) | RU2014117510A (enExample) |
| WO (1) | WO2013053767A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2714919C2 (ru) | 2013-08-30 | 2020-02-21 | Такеда Гмбх | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков |
| CA2948944A1 (en) * | 2014-05-19 | 2015-11-26 | Medimmune Limited | Treatment for rheumatoid arthritis |
| EP3464358A1 (en) | 2016-05-24 | 2019-04-10 | Medimmune Limited | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
| WO2018144334A1 (en) * | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| JP7495403B2 (ja) | 2018-11-09 | 2024-06-04 | キニクサ ファーマシューティカルズ， リミテッド | 巨細胞性動脈炎の治療 |
| WO2020096664A1 (en) | 2018-11-09 | 2020-05-14 | Kiniksa Pharmaceuticals, Ltd. | Treatment for giant cell arteritis |
| WO2020239090A1 (zh) * | 2019-05-31 | 2020-12-03 | 广州市雷德生物科技有限公司 | 一种类风湿关节炎相关的特异性多肽及其应用 |
| CN118949031A (zh) | 2019-06-03 | 2024-11-15 | 基尼克萨制药股份有限公司 | 用gm-csf拮抗剂治疗癌症 |
| US20210284744A1 (en) | 2020-03-15 | 2021-09-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| US20220184179A1 (en) | 2020-10-26 | 2022-06-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
| WO2025218746A1 (en) * | 2024-04-17 | 2025-10-23 | Sinomab Bioscience Limited | Methods of treating rheumatoid arthritis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| EP1137941B2 (en) | 1998-12-10 | 2013-09-11 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| MXPA04005080A (es) * | 2004-05-27 | 2005-11-30 | Aspid S A De C V | Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona. |
| ES2395839T3 (es) * | 2006-03-27 | 2013-02-15 | Medimmune Limited | Miembro de unión para el receptor GM-CSF |
| SG174026A1 (en) * | 2006-08-03 | 2011-09-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| WO2011097301A2 (en) * | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2012
- 2012-10-10 JP JP2014533950A patent/JP6239517B2/ja active Active
- 2012-10-10 ES ES12770487.2T patent/ES2660776T3/es active Active
- 2012-10-10 CA CA2851322A patent/CA2851322C/en active Active
- 2012-10-10 RU RU2014117510/15A patent/RU2014117510A/ru unknown
- 2012-10-10 US US14/349,706 patent/US20140335081A1/en not_active Abandoned
- 2012-10-10 WO PCT/EP2012/070074 patent/WO2013053767A1/en not_active Ceased
- 2012-10-10 EP EP12770487.2A patent/EP2766394B1/en active Active
- 2012-10-10 CN CN201280048532.1A patent/CN103906767A/zh active Pending
- 2012-10-10 AU AU2012322991A patent/AU2012322991B2/en not_active Ceased
-
2018
- 2018-01-24 AU AU2018200560A patent/AU2018200560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020223706B2 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| JP6877357B2 (ja) | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 | |
| JP6526037B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法 | |
| JP7434456B2 (ja) | 抗ｉｌ－１３抗体を使用する、ｉｌ－１３活性が有害である疾患の治療方法 | |
| JP2006522830A5 (enExample) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| RS58091B1 (sr) | Metode za tretiranje ili prevenciju astme davanjem antagonista il-4r | |
| JP2021523188A (ja) | Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 | |
| KR20150048887A (ko) | Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법 | |
| KR20220035272A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| JP2011506483A5 (enExample) | ||
| AU2022200690B2 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| JP2026062653A (ja) | シェーグレン症候群の処置 | |
| KR20210122810A (ko) | 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체 | |
| CA3164126A1 (en) | Antibodies for the treatment of chronic graft versus host disease | |
| KR20250011948A (ko) | 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법 | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| JP2002521491A (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| WO2025257781A1 (en) | Treatment of systemic sclerosis using anti-baff-r antibodies | |
| TW202434632A (zh) | 治療重症肌無力之方法 | |
| JP2024516019A (ja) | 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療 | |
| WO2025120567A1 (en) | Method of treatment of asthma | |
| HK1225635A1 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| HK1225635B (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same |